Neurocrine Biosciences, Inc. (NBIX) 은(는) 상장 기업입니다 헬스케어 섹터의 Drug Manufacturers - Specialty & Generic 산업에서 운영. 본사 소재지는 San Diego, CA, 미국. 현재 CEO는 Kyle W. Gano.
NBIX 을(를) 보유 IPO 날짜 1996-05-23, 1,800 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $13.13B.
Neurocrine Biosciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medications for neurological, endocrine, and psychiatric disorders. The company's marketed products include INGREZZA for tardive dyskinesia, ONGENTYS for Parkinson's disease, ORILISSA for endometriosis, and ORIAHNN for uterine fibroids, alongside a robust pipeline of clinical-stage candidates targeting epilepsy, major depressive disorder, anhedonia, and schizophrenia. Founded in 1992 and headquartered in San Diego, California, Neurocrine has established strategic partnerships with major pharmaceutical companies including Takeda, AbbVie, Mitsubishi Tanabe Pharma, and others to support its development and commercialization efforts across multiple therapeutic areas.
